Key Highlights

  • The two gainers are listed first and the two decliners second, each group ordered by the size of its move. The shared test is whether cash and data milestones line up with dated catalysts.
  • Aptevo Therapeutics (NASDAQ:APVO) gained 11.72% on transplant outcomes released Monday, October 26, 2026, while Alaunos Therapeutics (NASDAQ:TCRT) rose 6.31% with an acquisition and a financing of about USD 350 million behind it.
  • Rapport Therapeutics (NASDAQ:RAPP) slid 18.12% without a new release, and Enlivex Ltd. (NASDAQ:ENLV) dropped 7.41% in its first full session after a 1-for-16 reverse share split.
  • Funding visibility varies widely, from Rapport's cash of USD 436.1 million and a runway into the second half of 2029 to Aptevo's cash of USD 9.8 million. The Fed decision lands later on Wednesday, October 28, 2026.

Aptevo Therapeutics (NASDAQ:APVO): transplant data sitting on a thin cash balance

Building multispecific antibodies for blood cancers and solid tumours, Aptevo Therapeutics (NASDAQ:APVO) is a clinical-stage biotechnology company. In pre-market trading on Wednesday, October 28, 2026 it was at USD 1.43, up 11.72%, a gain that reverses the pre-market drop of Tuesday, October 27, 2026 and implies a prior close near USD 1.28 by simple arithmetic on the snapshot. Its newest item is the release of Monday, October 26, 2026 at 8:05 a.m. ET, reporting that 10 of 47 patients given the mipletamig combination in acute myeloid leukaemia went on to donor stem cell transplant. Nothing dated Tuesday, October 27, 2026 or Wednesday, October 28, 2026 was identified.

Regulatory discussions are planned for the first half of 2027, and nine of the transplanted patients came from the Phase 1b RAINIER trial. Cash and equivalents were USD 9.8 million at June 30, 2026, according to the quarterly update of Friday, August 14, 2026. A warrant inducement and private placement at USD 4.03 a share was announced on Wednesday, August 12, 2026. Net loss and earnings per share were not among the figures cited.

The optimistic view rests on the transplant outcomes and a 93% clinical benefit rate in frontline TP53-mutated disease. The cautious view rests on small patient numbers, the thin cash balance and dilution from the August placement. Investors should watch the SITC Annual Meeting, which starts on Wednesday, November 4, 2026.

Alaunos Therapeutics (NASDAQ:TCRT): a reshaped balance sheet and a dilution question

Alaunos Therapeutics (NASDAQ:TCRT) is a clinical-stage biotechnology company that has shifted from T-cell receptor oncology toward obesity and cardiopulmonary programmes. It traded at USD 2.19, up 6.31%, in Wednesday, October 28, 2026 pre-market trading. No company-specific announcement dated on or just before that day came with the move. The latest catalyst is the acquisition of Velaris Therapeutics, a private developer of therapies for pulmonary arterial hypertension, completed on Tuesday, October 13, 2026. The gain looks consistent with trading around that deal and thin liquidity, an inference.

A filing of Tuesday, October 13, 2026 laid out financing of about USD 350 million. Each Series C preferred share was priced at USD 1,435.70 and converts into 1,000 common shares once stockholders approve; common shares were priced at USD 1.4357, so by simple arithmetic the USD 2.19 quote is about 52.5% higher. Cash was about USD 0.354 million at March 31, 2026, and no revenue or loss figures were given in the filing.

The optimistic view rests on funding the company says should reach into 2029 and on its pulmonary hypertension pipeline, with clinical proof of concept for VLR199 expected in 2028. The cautious view rests on dilution, since conversion implies about 358.59 million common shares on an as-converted basis. Named risks include the stockholder vote, for which no date has been announced.

Rapport Therapeutics (NASDAQ:RAPP): the steepest fall with the longest runway

Rapport Therapeutics (NASDAQ:RAPP) is a clinical-stage company developing RAP-219 for focal onset seizures and acute bipolar mania. It traded at USD 22.55, down 18.12%, in Wednesday, October 28, 2026 pre-market trading. Simple arithmetic on that snapshot implies a prior close near USD 27.54. No company-specific announcement dated on or just before that day came with the move. The latest release, dated Tuesday, October 20, 2026 at 6:00 a.m. ET, reported topline results from the Phase 2 bipolar mania trial. The drop seems consistent with a repricing of those data and thin liquidity, an inference.

RAP-219 lowered Young Mania Rating Scale scores by 15.4 points versus 12.3 points on placebo in that release, a placebo-adjusted gain of 3.1 points at Week 3 among 253 adults, with a p-value of 0.045. A net loss of USD 56.6 million and research and development expense of USD 51.4 million were reported in the release of Wednesday, August 5, 2026. Cash stood at USD 436.1 million at Tuesday, June 30, 2026.

The optimistic view is that the primary endpoint was met and the cash position funds operations into the second half of 2029. The cautious view is that a p-value of 0.045 sits close to the conventional 0.05 threshold, and that Phase 3 bipolar mania trials are not expected before the second half of 2027.

Enlivex Ltd. (NASDAQ:ENLV): a post-split quote and a cost reduction plan

Allocetra for age-related osteoarthritis is being developed by Enlivex Ltd. (NASDAQ:ENLV), a clinical stage immunotherapy company that also runs a treasury strategy built around the Rain protocol. Pre-market on Wednesday, October 28, 2026 it was at USD 2.50, down 7.41%. Its release of Thursday, October 22, 2026 announced a 1-for-16 reverse share split, effective Tuesday, October 27, 2026, so the quote is split adjusted. No other company-specific announcement dated on or just before the session accompanied the move. A share count of about 1.5 million fits the move, an inference.

A plan to wind down research unrelated to its Phase 2b Allocetra trial in knee osteoarthritis and cut the workforce by about 60% was described in the release of Monday, October 19, 2026. Outstanding shares fell from 24,511,905 to about 1,531,995 after the split. Neither October release gave a net loss, a cash balance or a cash runway, so the financing position cannot be quantified here.

The optimistic view is that the plan concentrates spending on one asset. The cautious view is that two reverse splits within four months, plus the workforce reduction, signal financing strain. A private placement of about USD 400 million announced on Tuesday, July 28, 2026 required shareholder approval, and its status is not stated in the October releases.

Where Things Stand

The gap between gainers and fallers seems to follow how fresh the company news is and how clear the funding picture is, although thin liquidity is a plausible contributor in every case. Aptevo Therapeutics (NASDAQ:APVO) and Alaunos Therapeutics (NASDAQ:TCRT) rose with transaction or data news behind them, Rapport Therapeutics (NASDAQ:RAPP) fell after its data, and Enlivex Ltd. (NASDAQ:ENLV) traded after a reverse split.

The next catalysts are the Federal Reserve decision due later on Wednesday, October 28, 2026, the SITC meeting from Wednesday, November 4, 2026 and the fourth quarter 2026 safety data at Rapport. Pre-market prices are snapshots that can change, and this is not investment advice.